Statistical analysis
respiratory virus infections
RESPIRATORY VIRUS INFECTION, SARS-COV-2 INFECTION, SECONDARY, DISEASE MODEL, APPENDIX
Primary analysis was performed according to the intention-to-treat principle. The primary outcome was analyzed using a generalized linear mixed model (Poisson distribution) with the center as a random intercept, the center-by-period interaction as a random effect and the strategy (intervention versus control), period, and community incidence rate-by-period interaction as covariates.The logarithm of the number of patients was included as an offset term. The parameters of the model were estimated using a full maximum-likelihood method with the Laplace method (SAS PROC GLIMMIX). The In sensitivity analyses, the period was modeled as a binary variable; variables used for randomization (screening equipment, flow) and intervention-by-week since roll-out interaction were included as covariates. Another sensitivity analysis was performed at the center level.For patients with multiple tests in 24 h, a single result was considered; it was considered positive in the case of a positive result. ED visits and test results for the same patient separated by more than 24 h were considered separately.The implementation of ED screening for asymptomatic/paucisymptomatic patients was described. Factors associated with performing ED screening for asymptomatic/paucisymptomatic patients were analyzed among patients who were offered screening using a generalized linear mixed model (binomial distribution) with the center as a random intercept and the patient characteristics as fixed effects. Patients who accepted screening but whose screening test was not performed for feasibility concerns were not included in the analysis. Missing data for covariates ranged from 0.2% to 15.6%.The proportions of new SARS-CoV-2 infections and other respiratory virus infections diagnosed through ED screening for asymptomatic/paucisymptomatic patients were described, as well as patient characteristics. The factors associated with new SARS-CoV-2 diagnoses through this screening were analyzed using a generalized linear mixed model (binomial distribution) with the center as a random intercept and the patient characteristics as fixed effects. Missing data for covariates ranged from 0.6% to 12.8%.In both models described above, the unit of analysis was the patient. Parameters were estimated with the Laplace method, and the fixed effects were estimated using the containment method. The variables that were found to be significant at The proportions of new SARS-CoV-2 infections diagnosed through ED screening for asymptomatic/paucisymptomatic patients overall and per ED, and the same proportion through ED screening for all patients were compared to the proportions of positive tests through community screening for adults screened in the geographical departments of the Paris metropolitan region using the Miettinen–Nurminen (MN) method [Analysis for secondary outcomes used descriptive statistics, with numbers and proportions (qualitative data), and means, standard deviations or medians and the first quartile and third quartile (quantitative data). Differences and 95% CIs were estimated using the MN method (qualitative data) and the Brookmeyer–Crowley test (quantitative data).The analysis plan for estimating the incidence rate in the Paris metropolitan region is detailed below. The proportion of new diagnoses was considered among ED-tested patients. The proportion was calculated for patients screened through ED screening for asymptomatic/paucisymptomatic patients and for all patients screened. The results were compared to the predictions of an age-stratified disease model for transmission in the region, previously validated with serological data and used in France in 2020 to 2021 [The analysis was performed using SAS software (version 9.4; SAS Institute, Cary, North Carolina, USA) and R 4.1.3 (2022-03-10). The code of the transmission model developed in Python 3 is available [This study is reported as per the cluster randomized trials extension of the Consolidated Standards of Reporting Trials (CONSORT) guidelines (Appendix L in 